TOP TIERMARKET NEWSWIRE

News & sentiment

OS THERAPIES INC EQU Equity (OSTX) — News & AI sentiment

OS THERAPIES INC EQU Equity (OSTX) news roundup. 8 stories aggregated over the last 30 days. Average 30-day sentiment is 60.5/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

8

avg sentiment 60.5/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

OSTX news in the last 24 hours, 7 days, 30 days and 90 days

How much OSTX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	OSTX stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	8	60.5/100	OSTX headlines →
Last 90 days	26	58.7/100	OSTX headlines →

Latest stories on OSTX

OS Therapies Inc (OSTX) files 8-K

SEC 8-K50 · neutralgeneral

Oct 19

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

StockTitan52 · neutralgeneral

Oct 19

OSTX Rises as OS Therapies Reports 72.7% Three-Year Survival in Phase 2b Metastatic Osteosarcoma Study

MarketChameleon78 · bullishproduct/pr

Oct 6

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

StockTitan73 · bullishproduct/pr

Oct 6

OS Therapies bolsters leadership team amid commercialization push

TipRanks63 · neutralgeneral

Oct 5

OS Therapies Inc (OSTX) files 8-K

SEC 8-K50 · neutralgeneral

Oct 5

OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO

Seeking Alpha63 · neutralgeneral

Oct 1

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

StockTitan55 · neutralgeneral

Oct 1

OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

StockTitan63 · neutralproduct/pr

Sep 24

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

StockTitan63 · neutralproduct/pr

Sep 21

OSTX Gains FDA Alignment on Phase 3 Adaptive Design as MHRA Leads Project Orbis for OST-HER2

MarketChameleon67 · bullishproduct/pr

Sep 17

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

StockTitan67 · bullishproduct/pr

Sep 17

OS Therapies announces full alignment on UK authorization application

The Fly63 · neutralgeneral

Sep 15

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

StockTitan67 · bullishproduct/pr

Sep 15

OS Therapies Inc (OSTX) files 8-K

SEC 8-K50 · neutralgeneral

Sep 10

OS Therapies Inc (OSTX) files 8-K

SEC 8-K50 · neutralgeneral

Sep 9

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

StockTitan73 · bullishproduct/pr

Sep 8

Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight

PR Newswire63 · neutralgeneral

Sep 3

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

StockTitan63 · neutralproduct/pr

Sep 2

OS Therapies Inc (OSTX) files 8-K

SEC 8-K50 · neutralgeneral

Aug 21

OS Therapies GAAP EPS of -$0.20 misses by $0.03

Seeking Alpha34 · bearishearnings

Aug 17

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

Business Insider50 · neutralgeneral

Aug 17

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

StockTitan63 · neutralproduct/pr

Aug 13

OS Therapies Inc (OSTX) files 8-K

SEC 8-K50 · neutralgeneral

Aug 12

OS Therapies Settles Leonite Debt, Issues Bridge Financing

TipRanks56 · neutralgeneral

Aug 6

Open OSTX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →